K.v. Pharmaceutical Company

Drugtech Corporation

Other

Perrigo Pharma International Designated Activity Company

Sensient Colors Incorporated

Thomas C Riley

R Saul Levinson

Brian K Cheng

Robert C Cuca

Yury Lagoviyer

Mitchell I Kirschner

Denis Stotler

Marc S Hermelin

Keith S Lienhop

Beverly A Schad

Ronald S Harland

Galen G Lapka

Charles P Tharp

Elio Mariani

Eric H Van Ness

A pharmaceutical formulation to treat vaginal conditions in a human patient comprises:

Pharmaceutical delivery system

A pharmaceutical delivery system that releases an active agent in a controlled manner for an extended period in the vaginal cavity to treat or cure ailments associated with the vaginal cavity or proximal areas. The delivery system includes an applicator which is composed of a high internal phase emulsion, allowing the delivery system to adhere to the mueosal surfaces of the body, primarily the lining of vaginal cavity. The delivery system can maintain the high internal phase emulsion at a temperature of 86&#xb0; F. for at least one month, without decomposition or instability of the emulsion.

Delivery system

The present invention relates to a novel essentially pH neutral vaginal drug delivery system suitable for modified delivery of a therapeutically active material in the vaginal cavity. The vaginal drug delivery system comprises an essentially pH neutral emulsion having globules having two phases, an internal water soluble phase and an external water-insoluble phase or film, wherein the water-soluble interior phase contains a therapeutically active drug or drugs. One novel aspect of the vaginal drug delivery system is that the internal water soluble phase comprises an acidic buffered phase.

Bioadhesive drug delivery system

The present invention relates to a means for creating a mass having structural integrity, including a rapidly disintegratable tablet for administration with or without the use of water. The present invention has a wide variety of different uses and applications. One embodiment is a tablet intended for oral administration. The tablet comprises at least one active ingredient and a mixture of excipients. The excipients provide desired characteristics and physical properties and when the tablet is sintered or heated, excellent tablet binding characteristics are obtained. The tablet is intended primarily for oral administration and dissolves in the presence of water. Also disclosed is a process for the preparation of a rapidly disintegratable tablet for administration with or without the use of water. The process comprising dissolving at least one bulking agent and at least one structural agent in a suitable solvent, wherein the solvent provides high porosity upon drying; spray-drying or dispersing said dissolved mixture to obtain a bead or granulated product; dry blending at least one binding agent, and at least one active ingredient with the bead or granulated product to obtain a preformulation product or adding at least one active ingredient to the preformulation product dissolved or dispersed components before spray-drying or dispersing; compressing the preformulation product; and sintering or heating the preformulation product for a sufficient time and temperature to allow the binding agent to change status or melt and allow the binding agent to resolidify as the temperature is reduced to ambient temperature.

Means for creating a mass having structural integrity

A bioadherent, orally ingestible system, which comprises: a water-in-oil system having at least two phases, one phase comprises from about 75% to about 99% by volume of an internal hydrophylic phase and the other phase comprises from about 25% to about l% by volume of an external hydrophobic phase, wherein the external hydrophobic phase comprises two components, one component being about 3% to about 97% by volume of the hydrophobic phase of a hydrophobic oil and the other being about 97% to about 3% of an emulsifier having a HLB value less than about 10.

Long acting GI and esophageal protectant

A substantially tasteless pharmaceutical delivery system, which comprises a) an active material; and b) a spatially oriented matrix comprising (i) a wax core material having a melting point within the range of about 50.degree. C. and about 200.degree. C.; and (ii) a regional hydrophobic polymer material and method for making the same.

Tastemasked pharmaceutical materials

Systems and their methods of preparation and use that release an active agent in a controlled manner for an extended period in a vaginal cavity environment. The systems are capable of delivering the active agent for periods greater than three hours at a predictable rate to a predetermined site, the vaginal cavity.

Vaginal delivery systems and their methods of preparation and use

In a welding procedure for joining of adjacent, possibly partially enclosed metal components, such as pipe sections, wherein the welding procedure can be of a gas tungsten arc type such as a heli-arc type, or similar process, and wherein oxidation of metal frequently occurs within the components at the joinder point due to presence of oxygen in the region of weld during the welding procedure; introducing under pressure and at least initially pressure blowing, at a relatively high pressure, an inert gas into the interior of the components in a substantial swirling and interior surface wiping motion. The inert gas is blown through the components, from the entry end, beyond the weld region to rapidly, and substantially completely remove from the interior and weld region, any oxygen or other possible deleterious gas or material. Subsequently a lower pressure introduction of gas will serve to maintain the interior free of oxygen and the like. This procedure permits a clean, rapid welding of the elements in the absence of a build-up of undesired metal at the weld or juncture point, or undesired disturbance of the weld puddle which could cause defects in the weld.

Growing community of inventors

Manchester, MO, United States of America

Thomas C Riley